Marked N-acetylaspartate and choline metabolite changes in Parkinson's disease patients with mild cognitive impairment

Parkinsonism and Related Disorders

Volumn 19, Issue 3, 2013, Pages 329-334

  Nie, Kun ^a,b   Zhang, Yuhu ^b   Huang, Biao ^b   Wang, Limin ^b   Zhao, Jiehao ^b   Huang, Zhiheng ^b   Gan, Rong ^b   Wang, Lijuan ^b  

^a SOUTHERN MEDICAL UNIVERSITY   (China)

^b GUANGDONG PROVINCIAL PEOPLE'S HOSPITAL   (China)

Author keywords

Mild cognitive impairment; MR spectroscopy; Occipital lobe; Parkinson's disease; Posterior cingulate

Indexed keywords

BIOLOGICAL MARKER; CHOLINE; CREATINE; N ACETYLASPARTIC ACID;

ADULT; AMINO ACID METABOLISM; ARTICLE; BASAL GANGLION; BRAIN METABOLISM; CONTROLLED STUDY; DISEASE MARKER; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; METABOLITE; MILD COGNITIVE IMPAIRMENT; OCCIPITAL LOBE; PARKINSON DISEASE; POSTERIOR CINGULATE; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; SUBSTANTIA NIGRA;

AGED; ASPARTIC ACID; BIOLOGICAL MARKERS; BRAIN; BRAIN CHEMISTRY; CHOLINE; EARLY DIAGNOSIS; FEMALE; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MIDDLE AGED; MILD COGNITIVE IMPAIRMENT; PARKINSON DISEASE;

EID: 84874280340     PISSN: 13538020     EISSN: 18735126     Source Type: Journal    
DOI: 10.1016/j.parkreldis.2012.11.012     Document Type: Article

References (68)

1. Caviness J.N., Driver-Dunckley E., Connor D.J., Sabbagh M.N., Hentz J.G., Noble B., et al. Defining mild cognitive impairment in Parkinson's disease. Mov Disord 2007, 22:1272-1277.
2. Janvin C., Aarsland D., Larsen J.P., Hugdahl K. Neuropsychological profile of patients with Parkinson's disease without dementia. Dement Geriatr Cogn Disord 2003, 15:126-131.
3. Janvin C.C., Larsen J.P., Aarsland D., Hugdahl K. Subtypes of mild cognitive impairment in Parkinson's disease: progression to dementia. Mov Disord 2006, 21:1343-1349.
4. Adler C.H., Caviness J.N., Sabbagh M.N., Shill H.A., Connor D.J., Sue L., et al. Heterogeneous neuropathological findings in Parkinson's disease with mild cognitive impairment. Acta Neuropathol 2010, 120:827-828.
5. Jellinger K.A. Neuropathology in Parkinson's disease with mild cognitive impairment. Acta Neuropathol 2010, 120:829-830. [author reply 31].
6. McKinlay A., Grace R.C., Dalrymple-Alford J.C., Roger D. Cognitive characteristics associated with mild cognitive impairment in Parkinson's disease. Dement Geriatr Cogn Disord 2009, 28:121-129.
7. Song I.U., Kim J.S., Jeong D.S., Song H.J., Lee K.S. Early neuropsychological detection and the characteristics of Parkinson's disease associated with mild dementia. Parkinsonism Relat Disord 2008, 14:558-562.
8. Lyoo C.H., Jeong Y., Ryu Y.H., Rinne J.O., Lee M.S. Cerebral glucose metabolism of Parkinson's disease patients with mild cognitive impairment. Eur Neurol 2010, 64:65-73.
9. Gujar S.K., Maheshwari S., Bjorkman-Burtscher I., Sundgren P.C. Magnetic resonance spectroscopy. J Neuroophthalmol 2005, 25:217-226.
10. 1H NMR spectroscopy: N-acetyl-L-aspartate, creatine and choline. NMR Biomed 1991, 4:47-52.
11. Urenjak J., Williams S.R., Gadian D.G., Noble M. Proton nuclear magnetic resonance spectroscopy unambiguously identifies different neural cell types. J Neurosci 1993, 13:981-989.
12. Davie C.A., Wenning G.K., Barker G.J., Tofts P.S., Kendall B.E., Quinn N., et al. Differentiation of multiple system atrophy from idiopathic Parkinson's disease using proton magnetic resonance spectroscopy. Ann Neurol 1995, 37:204-210.
13. Clarke C.E., Lowry M. Basal ganglia metabolite concentrations in idiopathic Parkinson's disease and multiple system atrophy measured by proton magnetic resonance spectroscopy. Eur J Neurol 2000, 7:661-665.
14. Abe K., Terakawa H., Takanashi M., Watanabe Y., Tanaka H., Fujita N., et al. Proton magnetic resonance spectroscopy of patients with parkinsonism. Brain Res Bull 2000, 52:589-595.
15. 1H-MR spectroscopy in multiple system atrophy: NAA/Cr reduction in pontine base as a valuable diagnostic marker. J Neurol Neurosurg Psychiatry 2004, 75:103-109.
16. Miller B.L., Moats R.A., Shonk T., Ernst T., Woolley S., Ross B.D. Alzheimer disease: depiction of increased cerebral myo-inositol with proton MR spectroscopy. Radiology 1993, 187:433-437.
17. Shonk T.K., Moats R.A., Gifford P., Michaelis T., Mandigo J.C., Izumi J., et al. Probable Alzheimer disease: diagnosis with proton MR spectroscopy. Radiology 1995, 195:65-72.
18. Jessen F., Block W., Traber F., Keller E., Flacke S., Papassotiropoulos A., et al. Proton MR spectroscopy detects a relative decrease of N-acetylaspartate in the medial temporal lobe of patients with AD. Neurology 2000, 55:684-688.
19. 1H MRS study. Neurology 2000, 55:210-217.
20. Bowen B.C., Block R.E., Sanchez-Ramos J., Pattany P.M., Lampman D.A., Murdoch J.B., et al. Proton MR spectroscopy of the brain in 14 patients with Parkinson disease. AJNR Am J Neuroradiol 1995, 16:61-68.
21. Summerfield C., Gomez-Anson B., Tolosa E., Mercader J.M., Marti M.J., Pastor P., et al. Dementia in Parkinson disease: a proton magnetic resonance spectroscopy study. Arch Neurol 2002, 59:1415-1420.
22. Camicioli R.M., Korzan J.R., Foster S.L., Fisher N.J., Emery D.J., Bastos A.C., et al. Posterior cingulate metabolic changes occur in Parkinson's disease patients without dementia. Neurosci Lett 2004, 354:177-180.
23. Griffith H.R., den Hollander J.A., Okonkwo O.C., O'Brien T., Watts R.L., Marson D.C. Brain metabolism differs in Alzheimer's disease and Parkinson's disease dementia. Alzheimers Dement 2008, 4:421-427.
24. Griffith H.R., den Hollander J.A., Okonkwo O.C., O'Brien T., Watts R.L., Marson D.C. Brain N-acetylaspartate is reduced in Parkinson disease with dementia. Alzheimer Dis Assoc Disord 2008, 22:54-60.
25. Molina J.A., Garcia-Segura J.M., Benito-Leon J., Gomez-Escalonilla C., del Ser T., Martinez V., et al. Proton magnetic resonance spectroscopy in dementia with Lewy bodies. Eur Neurol 2002, 48:158-163.
26. Gelb D.J., Oliver E., Gilman S. Diagnostic criteria for Parkinson disease. Arch Neurol 1999, 56:33-39.
27. Zheng J., Sun S., Qiao X., Liu Y. Depression in patients with Parkinson's disease and the associated features. J Huazhong Univ Sci Technol Med Sci 2009, 29:725-728.
28. Leentjens A.F., Verhey F.R., Lousberg R., Spitsbergen H., Wilmink F.W. The validity of the Hamilton and Montgomery-Asberg depression rating scales as screening and diagnostic tools for depression in Parkinson's disease. Int J Geriatr Psychiatry 2000, 15:644-649.
29. Weintraub D., Oehlberg K.A., Katz I.R., Stern M.B. Test characteristics of the 15-item geriatric depression scale and Hamilton depression rating scale in Parkinson disease. Am J Geriatr Psychiatry 2006, 14:169-175.
30. Cummings J.L. The Neuropsychiatric Inventory: assessing psychopathology in dementia patients. Neurology 1997, 48:S10-S16.
31. Cummings J.L., Mega M., Gray K., Rosenberg-Thompson S., Carusi D.A., Gornbein J. The Neuropsychiatric inventory: comprehensive assessment of psychopathology in dementia. Neurology 1994, 44:2308-2314.
32. Zhang Zhenxin, Hong Xia, Li Hui, Zhao Jiehao, Huang Juebin, Wei Jing, et al. The mini-mental state examination in the Chinese residents population aged 55 years and over in the urban and rural areas of Beijing. Chin J Neurol 1999, 32:149-153.
33. Dufouil C., Clayton D., Brayne C., Chi L.Y., Dening T.R., Paykel E.S., et al. Population norms for the MMSE in the very old: estimates based on longitudinal data. Mini-Mental State Examination. Neurology 2000, 55:1609-1613.
34. Katzman R., Zhang M.Y., Ouang Ya Q., Wang Z.Y., Liu W.T., Yu E., et al. A Chinese version of the Mini-Mental State Examination; impact of illiteracy in a Shanghai dementia survey. J Clin Epidemiol 1988, 41:971-978.
35. Hoops S., Nazem S., Siderowf A.D., Duda J.E., Xie S.X., Stern M.B., et al. Validity of the MoCA and MMSE in the detection of MCI and dementia in Parkinson disease. Neurology 2009, 73:1738-1745.
36. Wen H.B., Zhang Z.X., Niu F.S., Li L. The application of Montreal cognitive assessment in urban Chinese residents of Beijing. Zhonghua Nei Ke Za Zhi 2008, 47:36-39.
37. Gill D.J., Freshman A., Blender J.A., Ravina B. The Montreal cognitive assessment as a screening tool for cognitive impairment in Parkinson's disease. Mov Disord 2008, 23:1043-1046.
38. Wechsler D. Wechsler memory scale 1997, Psychological Corporation, San Antonio. 3rd ed.
39. Wechsler D. WAIS-III, WMS-III technical manual 1997, Psychological Corporation, San Antonio.
40. Sunderland T., Hill J.L., Mellow A.M., Lawlor B.A., Gundersheimer J., Newhouse P.A., et al. Clock drawing in Alzheimer's disease. A novel measure of dementia severity. J Am Geriatr Soc 1989, 37:725-729.
41. Mosimann U.P., Mather G., Wesnes K.A., O'Brien J.T., Burn D.J., McKeith I.G. Visual perception in Parkinson disease dementia and dementia with Lewy bodies. Neurology 2004, 63:2091-2096.
42. Petersen R.C., Doody R., Kurz A., Mohs R.C., Morris J.C., Rabins P.V., et al. Current concepts in mild cognitive impairment. Arch Neurol 2001, 58:1985-1992.
43. Dubois B., Burn D., Goetz C., Aarsland D., Brown R.G., Broe G.A., et al. Diagnostic procedures for Parkinson's disease dementia: recommendations from the movement disorder society task force. Mov Disord 2007, 22:2314-2324.
44. Emre M., Aarsland D., Brown R., Burn D.J., Duyckaerts C., Mizuno Y., et al. Clinical diagnostic criteria for dementia associated with Parkinson's disease. Mov Disord 2007, 22:1689-1707. [quiz 837].
45. Lewis S.J., Foltynie T., Blackwell A.D., Robbins T.W., Owen A.M., Barker R.A. Heterogeneity of Parkinson's disease in the early clinical stages using a data driven approach. J Neurol Neurosurg Psychiatry 2005, 76:343-348.
46. Hosokai Y., Nishio Y., Hirayama K., Takeda A., Ishioka T., Sawada Y., et al. Distinct patterns of regional cerebral glucose metabolism in Parkinson's disease with and without mild cognitive impairment. Mov Disord 2009, 24:854-862.
47. Hu M.T., Taylor-Robinson S.D., Chaudhuri K.R., Bell J.D., Labbe C., Cunningham V.J., et al. Cortical dysfunction in non-demented Parkinson's disease patients: a combined (31)P-MRS and (18)FDG-PET study. Brain 2000, 123(Pt 2):340-352.
48. Firbank M.J., Harrison R.M., O'Brien J.T. A comprehensive review of proton magnetic resonance spectroscopy studies in dementia and Parkinson's disease. Dement Geriatr Cogn Disord 2002, 14:64-76.
49. Burton E.J., McKeith I.G., Burn D.J., O'Brien J.T. Brain atrophy rates in Parkinson's disease with and without dementia using serial magnetic resonance imaging. Mov Disord 2005, 20:1571-1576.
50. Beyer M.K., Aarsland D. Grey matter atrophy in early versus late dementia in Parkinson's disease. Parkinsonism Relat Disord 2008, 14:620-625.
51. Ramirez-Ruiz B., Marti M.J., Tolosa E., Bartres-Faz D., Summerfield C., Salgado-Pineda P., et al. Longitudinal evaluation of cerebral morphological changes in Parkinson's disease with and without dementia. J Neurol 2005, 252:1345-1352.
52. Modrego P.J., Fayed N., Pina M.A. Conversion from mild cognitive impairment to probable Alzheimer's disease predicted by brain magnetic resonance spectroscopy. Am J Psychiatry 2005, 162:667-675.
53. Metastasio A., Rinaldi P., Tarducci R., Mariani E., Feliziani F.T., Cherubini A., et al. Conversion of MCI to dementia: role of proton magnetic resonance spectroscopy. Neurobiol Aging 2006, 27:926-932.
54. Valenzuela M.J., Sachdev P. Magnetic resonance spectroscopy in AD. Neurology 2001, 56:592-598.
55. 1H magnetic resonance spectroscopy, cognitive function, and apolipoprotein E genotype in normal aging, mild cognitive impairment and Alzheimer's disease. J Int Neuropsychol Soc 2002, 8:934-942.
56. 1H-MRS evaluation of metabolism in Alzheimer's disease and vascular dementia. Neurol Res 2004, 26:488-495.
57. Braak H., Braak E., Yilmazer D., de Vos R.A., Jansen E.N., Bohl J. Pattern of brain destruction in Parkinson's and Alzheimer's diseases. J Neural Transm 1996, 103:455-490.
58. Galvin J.E., Pollack J., Morris J.C. Clinical phenotype of Parkinson disease dementia. Neurology 2006, 67:1605-1611.
59. Pletnikova O., West N., Lee M.K., Rudow G.L., Skolasky R.L., Dawson T.M., et al. Abeta deposition is associated with enhanced cortical alpha-synuclein lesions in Lewy body diseases. Neurobiol Aging 2005, 26:1183-1192.
60. Neumann M., Muller V., Kretzschmar H.A., Haass C., Kahle P.J. Regional distribution of proteinase K-resistant alpha-synuclein correlates with Lewy body disease stage. J Neuropathol Exp Neurol 2004, 63:1225-1235.
61. Braak H., Ghebremedhin E., Rub U., Bratzke H., Del Tredici K. Stages in the development of Parkinson's disease-related pathology. Cell Tissue Res 2004, 318:121-134.
62. Jellinger K.A. Alpha-synuclein pathology in Parkinson's and Alzheimer's disease brain: incidence and topographic distribution-a pilot study. Acta Neuropathol 2003, 106:191-201.
63. Mattila P.M., Rinne J.O., Helenius H., Dickson D.W., Roytta M. Alpha-synuclein-immunoreactive cortical Lewy bodies are associated with cognitive impairment in Parkinson's disease. Acta Neuropathol 2000, 100:285-290.
64. Griffith H.R., Stewart C.C., den Hollander J.A. Proton magnetic resonance spectroscopy in dementias and mild cognitive impairment. Int Rev Neurobiol 2009, 84:105-131.
65. 18F]fluorodopa positron emission tomographic study. Arch Neurol 2000, 57:470-475.
66. Lucetti C., Del Dotto P., Gambaccini G., Ceravolo R., Logi C., Berti C., et al. Influences of dopaminergic treatment on motor cortex in Parkinson disease: a MRI/MRS study. Mov Disord 2007, 22:2170-2175.
67. Clarke C.E., Lowry M., Horsman A. Unchanged basal ganglia N-acetylaspartate and glutamate in idiopathic Parkinson's disease measured by proton magnetic resonance spectroscopy. Mov Disord 1997, 12:297-301.
68. Ellis C.M., Lemmens G., Williams S.C., Simmons A., Dawson J., Leigh P.N., et al. Changes in putamen N-acetylaspartate and choline ratios in untreated and levodopa-treated Parkinson's disease: a proton magnetic resonance spectroscopy study. Neurology 1997, 49:438-444.